Last updated: September 5, 2026
Pitolisant hydrochloride, marketed in the United States as WAKIX by Harmony Biosciences, is a first-in-class histamine H3-receptor inverse agonist for narcolepsy. Its commercial profile is defined by rapid prescription growth, expansion into pediatric narcolepsy, high specialty-drug pricing, and a patent estate that is intended to delay generic entry beyond the earliest compound-patent expiry.
WAKIX revenue has grown from a launch-stage product into Harmony Biosciences' primary commercial asset. The main risks are concentration in one product, payer restrictions, future Paragraph IV litigation, and competition from established narcolepsy therapies and newer agents such as sodium oxybate formulations.
What is pitolisant hydrochloride and how is WAKIX used?
Pitolisant hydrochloride increases histaminergic neurotransmission through inverse agonism at the H3 receptor. Unlike sodium oxybate and traditional stimulants, pitolisant is not a controlled substance in the United States.
The FDA approved WAKIX in August 2019 for excessive daytime sleepiness or cataplexy in adults with narcolepsy. In 2023, the FDA expanded the indication to pediatric patients aged 6 years and older with excessive daytime sleepiness or cataplexy associated with narcolepsy.[1]
| Product |
Active ingredient |
Sponsor |
FDA indication |
U.S. approval |
| WAKIX |
Pitolisant hydrochloride |
Harmony Biosciences |
Excessive daytime sleepiness and cataplexy in narcolepsy |
2019 |
| WAKIX pediatric indication |
Pitolisant hydrochloride |
Harmony Biosciences |
Narcolepsy in patients aged 6 and older |
2023 |
| WAKIX tablets |
Pitolisant hydrochloride |
Harmony Biosciences |
Oral tablets, 4.45 mg and 17.8 mg |
Approved |
WAKIX is titrated over several weeks. The label identifies important contraindications and precautions, including severe hepatic impairment and QT-interval prolongation risks.[1]
How large is the pitolisant hydrochloride market?
The addressable U.S. market is the narcolepsy population treated for excessive daytime sleepiness, cataplexy, or both. The commercial opportunity is larger than the diagnosed population currently receiving therapy because narcolepsy is underdiagnosed and many patients cycle through multiple treatments.
Market growth is supported by:
- Increased physician recognition of narcolepsy.
- Greater use of pharmacologic treatment for cataplexy.
- Pediatric label expansion.
- Prescriber interest in a noncontrolled oral therapy.
- Commercial investment by Harmony in sleep-specialty sales and patient services.
- Long-term treatment duration for chronic narcolepsy.
The market remains competitive. Key alternatives include modafinil, armodafinil, solriamfetol, sodium oxybate, low-sodium oxybate, methylphenidate, and amphetamine products. These drugs differ materially in mechanism, abuse potential, dosing burden, efficacy across symptoms, and payer positioning.
How does pitolisant compare with competing narcolepsy drugs?
| Drug or class |
Main commercial strength |
Main limitation relative to pitolisant |
| Modafinil and armodafinil |
Established use and lower cost |
Less differentiated efficacy; controlled-substance restrictions may apply |
| Solriamfetol |
Strong wake-promoting activity |
Controlled substance; cardiovascular and payer considerations |
| Sodium oxybate |
Established efficacy for cataplexy and sleepiness |
Complex nighttime dosing, abuse controls, tolerability and access burden |
| Low-sodium oxybate |
Reduced sodium exposure versus traditional oxybate |
Complex administration and specialty distribution |
| Stimulants |
Familiarity and rapid symptomatic effect |
Abuse potential, tolerability, and controlled-substance status |
| Pitolisant |
Noncontrolled oral therapy with activity against sleepiness and cataplexy |
Higher branded cost, titration, QT and drug-interaction considerations |
Pitolisant's commercial differentiation is strongest in patients who need treatment for both excessive daytime sleepiness and cataplexy but face barriers with controlled substances or oxybate administration.
What is the financial trajectory for Harmony Biosciences and WAKIX?
WAKIX is Harmony Biosciences' economic center. Revenue growth has been driven primarily by prescription expansion rather than a broad product portfolio.
Public company filings show a steep increase in net product revenue after launch. Reported figures vary slightly depending on whether a source presents net product revenue, total revenue, or rounded figures.
| Fiscal year |
Approximate WAKIX or company revenue |
Commercial position |
| 2020 |
Approximately $76 million |
Early commercial launch |
| 2021 |
Approximately $150 million |
Expanding narcolepsy penetration |
| 2022 |
Approximately $395 million |
Rapid specialty-market adoption |
| 2023 |
Approximately $550 million |
Scaled commercial platform |
| 2024 |
Approximately $720 million |
Continued growth before broader generic risk |
The 2020-2024 trajectory represents a compound annual growth rate of roughly 75%, although that calculation begins from a low launch base. Growth should moderate as the product penetrates a larger share of diagnosed patients and as the company faces payer-management pressure.
Revenue quality is favorable in several respects. WAKIX is a chronic-use product, has limited direct generic competition as of the latest publicly available filings, and benefits from a specialty pharmacy infrastructure. The risks are concentration and market access. A substantial portion of Harmony's revenue depends on one molecule and one therapeutic area.
What factors will determine future WAKIX revenue?
The principal revenue variables are:
- New patient starts and diagnosis rates.
- Persistence after initial titration.
- Pediatric adoption following the 2023 label expansion.
- Net price after rebates, discounts, and patient assistance.
- Commercial and government reimbursement.
- Generic entry timing.
- Expansion into additional sleep-related indications.
- Competition from oxybate products and wake-promoting agents.
A pediatric indication can extend market penetration, but pediatric uptake may develop more slowly because diagnosis is difficult and treatment decisions involve pediatric neurologists, sleep specialists, and caregivers.
What patents protect pitolisant hydrochloride and WAKIX?
WAKIX protection is based on a combination of active-ingredient, formulation, solid-form, and method-of-use patents. The exact Orange Book listing must be read against the current FDA publication because listed patents, pediatric extensions, terminal disclaimers, and litigation certifications can change.
Key patent categories include:
| Patent category |
Commercial purpose |
| Active pharmaceutical ingredient |
Protects pitolisant or core chemical subject matter |
| Solid form and crystalline form |
Limits substitution with a specific pharmaceutical form |
| Pharmaceutical composition |
Protects dosage-form composition and excipient combinations |
| Method of treatment |
Covers treatment of narcolepsy, excessive daytime sleepiness, or cataplexy |
| Pediatric use |
Can support additional market exclusivity where statutory requirements are met |
| Manufacturing process |
Raises development and scale-up barriers for generic applicants |
Public patent databases identify a group of U.S. patents associated with pitolisant, including patents in the US8,759,353 and US9,566,213 families and later patents directed to formulations, solid forms, and treatment methods. Expiration dates vary by patent and may be affected by patent-term adjustment, terminal disclaimers, and pediatric exclusivity.[2][3]
Because the commercial protection does not depend on one patent alone, a generic applicant may need to address several distinct claim sets. Method-of-use patents can be particularly important where the product's approved indications are clinically specific and the generic applicant must use a label that avoids patented indications.
When does pitolisant lose exclusivity?
There is no single WAKIX exclusivity date. The practical loss-of-exclusivity date depends on:
- The earliest unexpired Orange Book patent.
- The scope of each listed patent.
- Paragraph IV litigation outcomes.
- Any settlement restrictions.
- FDA regulatory exclusivity.
- Pediatric exclusivity.
- Whether a generic can obtain approval with a carved-out label.
The original U.S. regulatory exclusivity period for a new chemical entity generally lasts four years from approval, with the five-year NCE framework affecting when an ANDA may be submitted. WAKIX's commercial protection therefore relies primarily on patents rather than continuing NCE exclusivity.[4]
The earliest listed patents appear to expire around the end of the 2020s or early 2030s, while later formulation and method patents may extend into the mid-to-late 2030s. The earliest possible generic launch is not necessarily the earliest listed patent expiry. A first-filer may launch at risk, win litigation, settle for an earlier date, or be blocked by later patents.
What is the Orange Book status of WAKIX?
WAKIX is an FDA-approved small-molecule drug and is eligible for Orange Book patent listings. It is not a biologic and therefore does not face biosimilar competition under the Public Health Service Act.
The Orange Book is commercially important because an ANDA applicant must certify against listed patents. A Paragraph IV certification asserts that a listed patent is invalid, unenforceable, or not infringed. If the patent holder sues within the statutory period, FDA approval may be subject to a 30-month stay, subject to litigation developments and court decisions.[4][5]
The relevant diligence points are:
- Current Orange Book patent numbers.
- Listed expiration dates.
- Whether each patent covers the approved product or a method of use.
- Whether pediatric exclusivity changes the effective date.
- ANDA applicants and certification dates.
- Any court-ordered or settlement-based launch date.
Which companies are challenging WAKIX patents?
The main threat is expected from generic pharmaceutical companies that can file ANDAs for pitolisant hydrochloride tablets. Public filings have disclosed Paragraph IV litigation involving ANDA challengers, including Teva and Apotex-related entities. The precise defendant group, asserted patents, and procedural status should be tracked through federal court dockets and Harmony's periodic reports.[6]
A successful Paragraph IV challenge could compress the exclusivity period and reduce WAKIX net sales rapidly because narcolepsy therapies are chronic prescriptions and generic substitution can be substantial. A settlement could produce a controlled launch date, authorized generic arrangement, or other market-entry terms.
What generic launch scenarios exist?
| Scenario |
Likely commercial effect |
| No challenge succeeds before core patent expiry |
WAKIX retains branded pricing until the first relevant expiry |
| Early settlement launch |
Revenue declines from the agreed entry date, often before full patent expiry |
| Court invalidation or non-infringement finding |
Rapid generic erosion, subject to appeals and later patents |
| Carved-out generic label |
Partial competition focused on unpatented indications |
| Authorized generic launch |
Lower-price competition controlled by the brand owner |
| Later formulation patents upheld |
Generic may face delayed or limited substitution |
The most important commercial distinction is between an ANDA approval date and an actual launch date. Approval can occur during a patent dispute, while commercial marketing may remain restricted by settlement or court order.
What patent litigation affects pitolisant hydrochloride?
Pitolisant litigation is likely to center on claim construction, obviousness, written description, enablement, infringement, and the scope of method-of-use claims. Formulation and solid-form patents may be challenged on obviousness or lack of adequate disclosure.
The litigation risk is higher if:
- Multiple generic applicants file Paragraph IV certifications.
- The earliest patents have narrow claims.
- Later patents cover commercially unavoidable tablet characteristics.
- Method-of-use patents cover the full FDA label.
- Harmony relies on a limited number of high-value patents.
The risk is lower if the portfolio contains overlapping claims that protect the active ingredient, marketed dosage form, and clinically important indications independently.
How strong is the pitolisant patent estate?
The estate is commercially meaningful but should not be treated as impenetrable. Its strength has four dimensions:
| Dimension |
Assessment |
| Product differentiation |
Strong: noncontrolled H3 inverse agonist with two major narcolepsy symptoms on label |
| Regulatory position |
Strong: FDA-approved adult and pediatric indications |
| Patent breadth |
Moderate to strong, depending on validity and enforceability of later patents |
| Generic vulnerability |
Meaningful once ANDA challengers reach litigation or settlement |
The strongest protection comes from layering. A patent portfolio that includes only one composition patent is vulnerable to a single adverse ruling. A portfolio combining active-ingredient, solid-form, tablet, and method claims creates several litigation paths, although each claim must survive separate validity and infringement analysis.
Manufacturing know-how can also delay generic entry. Generic developers must establish impurity controls, polymorph consistency, dissolution, stability, and bioequivalence. These barriers are regulatory and technical rather than substitutes for patent protection.
Is pitolisant hydrochloride exposed to biosimilar risk?
No. Pitolisant hydrochloride is a chemically synthesized small molecule, not a biologic. WAKIX faces generic-drug risk through the ANDA pathway, not biosimilar competition under the abbreviated biologics framework.
The practical consequences are significant:
- Generic applicants can rely on pharmaceutical equivalence and bioequivalence.
- Interchangeability rules differ from those for biologics.
- The development timeline can be shorter than for a complex biologic.
- Patent litigation under the Hatch-Waxman framework is the main access dispute.
What licensing deals support pitolisant commercialization?
Pitolisant was developed by Bioprojet and commercialized in the United States by Harmony Biosciences under a license arrangement. Harmony obtained U.S. rights to pitolisant and built the U.S. commercial infrastructure around WAKIX. Bioprojet retains significance as the originator and international rights holder.
The licensing structure creates both value and cost considerations. Harmony gains access to an established clinical asset without discovering the molecule internally, while royalty obligations and milestone economics reduce product-level profitability. The agreement also ties Harmony's commercial strategy to the continued availability of rights from the originator.
What is the competitive outlook for WAKIX?
WAKIX is positioned between traditional stimulants and oxybate products. It has a clinically differentiated mechanism and avoids controlled-substance classification, but it competes in a market where physicians have multiple established therapies.
Near-term growth should come from deeper penetration in adult narcolepsy and pediatric adoption. Longer-term performance depends on maintaining reimbursement, defending patents, and identifying additional indications that can support the commercial platform.
The principal strategic risks are:
- A successful Paragraph IV challenge.
- Earlier-than-expected settlement-based generic entry.
- Lower net pricing from payer controls.
- Slower pediatric uptake.
- Competitive improvement in oxybate delivery or wake-promoting therapies.
- Dependence on one major marketed product.
Key Takeaways
- Pitolisant hydrochloride is marketed in the United States as WAKIX by Harmony Biosciences.
- FDA-approved uses cover excessive daytime sleepiness and cataplexy in adult and pediatric narcolepsy.
- WAKIX revenue increased sharply after launch and reached approximately $700 million in annual sales by 2024, based on company-reported financial disclosures.
- The product is a small molecule and faces generic, not biosimilar, competition.
- The patent estate includes active-ingredient, formulation, solid-form, and method-of-use protection.
- Paragraph IV litigation involving generic applicants, including Teva and Apotex-related entities, is the central access risk.
- The effective loss-of-exclusivity date depends on the surviving patent claims, litigation outcomes, settlements, and any pediatric extension.
- Harmony's financial exposure is high because WAKIX represents the company's principal commercial asset.
FAQs About Pitolisant Hydrochloride Market and Patent Risk
What company makes WAKIX?
Harmony Biosciences markets WAKIX in the United States under rights obtained from Bioprojet, the originator of pitolisant.
Is pitolisant hydrochloride a stimulant?
No. Pitolisant is a histamine H3-receptor inverse agonist. It is a wake-promoting medicine but is pharmacologically distinct from amphetamine stimulants and methylphenidate.
Is WAKIX a controlled substance?
WAKIX is not federally scheduled as a controlled substance in the United States, which is a key commercial distinction from several competing narcolepsy therapies.
Can a generic version of WAKIX be substituted automatically?
Automatic substitution depends on FDA approval, state pharmacy law, the approved generic label, and the status of listed patents and litigation. An ANDA approval alone does not guarantee immediate commercial substitution.
Does pitolisant have uses outside narcolepsy?
Pitolisant has been studied in other sleep and neurologic conditions, but the principal U.S. commercial indication is narcolepsy. Additional indications would require FDA approval and could generate separate method-of-use patent opportunities.
References
- U.S. Food and Drug Administration. (2023). WAKIX (pitolisant hydrochloride) prescribing information. https://www.accessdata.fda.gov
- U.S. Patent and Trademark Office. (n.d.). Patent Center and patent examination data for pitolisant-related U.S. patents. https://patentcenter.uspto.gov
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application regulatory framework and patent certifications. https://www.fda.gov/drugs
- U.S. Code, 21 U.S.C. ยง 355. (2024). New drugs and antibiotics. https://uscode.house.gov
- Harmony Biosciences Holdings, Inc. (2024). Annual report on Form 10-K. https://investors.harmonybiosciences.com
